AXL was also highly expressed in a subset of EGFR-mutant NSCLC patients, and baseline high expression was associated with a lower response rate to subsequent EGFR inhibitor therapy, suggesting that a subset of cells with an AXL high drug-tolerant phenotype may pre-exist in EGFR TKI therapy. The gene discussed is AXL; the disease is non-small cell lung carcinoma.